Medical/Pharmaceuticals
Harbour BioMed Announces Positive Profit Alert for 2025 Interim Results
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, July 27, 2025 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company focused on the discovery and development of novel antibody therapeutics in immunology and oncology, today announced a positive prof...
2025-07-28 08:11
2429
Elpis Biopharmaceuticals Signs Memorandum of Understanding with National Cancer Centre Singapore to Conduct Translational Cell Therapy Research in Singapore
Collaboration focuses on advancing clinically validated armored CAR technologies into first-in-human trials inSingapore and accelerate translational research from bench-to-bedside SINGAPORE and LEXINGTON, Mass., July 28, 2025 /PRNewswire/ -- Elpis Biopharmaceuticals, a clinical-stage cell therap...
2025-07-28 07:33
1949
Phase II Stage Of Pivotal Clinical Trial Of KX-826 Tincture 1.0% For The Treatment Of Male Adult Aga In China Reached Primary Endpoint
SUZHOU, China, July 26, 2025 /PRNewswire/ -- The Kintor Pharmaceutical Limited (the "Company") is pleased to announce that the Phase II Stage of the Pivotal Clinical Trial of its in-house developed and potential first-in-class KX-826 tincture 1.0% for the treatment of AGA has obtained top-line re...
2025-07-26 07:30
4222
Shanton Receives Fast Track Designation from US FDA for Refractory Gout Program
SAP-001 is Shanton's lead investigational compound with First- and Best-in-Class potential in uncontrolled gout SINGAPORE and PRINCETON, N.J., July 25, 2025 /PRNewswire/ -- Shanton Pharma, a clinical-stage biotech company developing a novel treatment for gout, today announced that FDA has design...
2025-07-25 22:59
3913
Phase II Stage Of Pivotal Clinical Trial Of KX-826 Tincture 1.0% For The Treatment Of Male Adult Aga In China Reached Primary Endpoint
SUZHOU, China, July 25, 2025 /PRNewswire/ -- The Kintor Pharmaceutical Limited (the "Company") is pleased to announce that the Phase II Stage of the Pivotal Clinical Trial of its in-house developed and potential first-in-class KX-826 tincture 1.0% for the treatment of AGA has obtained top-line re...
2025-07-25 20:30
3607
MALAYSIA HEALTHCARE TRAVEL COUNCIL LAUNCHES MYMT 2026, MALAYSIA'S FIRST MEDICAL TOURISM YEAR
KUALA LUMPUR, Malaysia, July 25, 2025 /PRNewswire/ -- The Malaysia Healthcare Travel Council (MHTC) launchedMalaysia Year of Medical Tourism (MYMT) 2026 today at the Malaysia International Trade and Exhibition Centre (MITEC). The Honourable Datuk Seri Dr. Dzulkefly Ahmad, Minister of Health Ma...
2025-07-25 14:00
3293
Everest Medicines Announces Share Placement to Raise Approximately HK$1,572.50 Million
SHANGHAI, July 25, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest" or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that it has entered into a placing and...
2025-07-25 10:30
3202
Leads Biolabs Lists on HKEX, Raising USD 189 Million Through Initial Public Offering
NANJING, China, July 25, 2025 /PRNewswire/ -- On 25 July, 2025 (China Time), Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company") listed on the Main Board of The Stock Exchange of Hong Kong Limited (HKEX) under the stock code "09887". The clinical-stage biotech company priced its I...
2025-07-25 09:00
3386
Colorcon Celebrates Grand Opening of New Manufacturing Facility in Malaysia
Johor plant is Colorcon's 7th major film coating plant and 16th manufacturing facility worldwide HARLEYSVILLE, Pa. and JOHOR, Malaysia, July 24, 2025 /PRNewswire/ -- Colorcon, a global leader of film coating systems, specialty excipients, controlled release formulations and controlled atmosphere...
2025-07-24 22:00
3130
NYSE Content Advisory: Pre-Market update + McGraw Hill, Accelerant IPO on NYSE
NEW YORK, July 24, 2025 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins. NYSE Content Advisory: Pre-Market update + McGraw Hill, Acceleran...
2025-07-24 21:00
2863
AMSC Malaysia 2025 Set to Spotlight World-Class Expertise and Innovation in Aesthetic Medicine and Surgery
KUALA LUMPUR, Malaysia, July 24, 2025 /PRNewswire/ -- The Aesthetic Medicine &
Surgery Conference & Exhibition (AMSC)
2025-07-24 20:24
4092
OSR Holdings Enters into Term Sheet to Acquire Woori IO, a Pioneer in Noninvasive Glucose Monitoring Technology
BELLEVUE, Wash. and SEOUL, South Korea, July 24, 2025 /PRNewswire/ -- OSR Holdings, Inc. (NASDAQ: OSRH), a global healthcare company advancing biomedical and wellness innovation, today announced it has signed a term sheet ("Term Sheet") with Woori IO Co., Ltd. ("WORIO"), a South Korean medical de...
2025-07-24 19:30
2518
Fapon at ADLM 2025: One-stop IVD Solutions & Deepened US Commitment
CHICAGO, July 24, 2025 /PRNewswire/ -- Fapon, a global leader in life sciences, will unveil its innovative one-stop IVD solutions at ADLM 2025, fromJuly 29 to 31 in Chicago, IL. Fapon aims to be the trusted global partner for laboratories and IVD manufacturers with advanced innovations and dedica...
2025-07-24 19:00
2086
Seegene unveils the world's first unattended PCR automation, igniting a global diagnostic paradigm shift at ADLM 2025
* Fully Unmanned— CURECA™, the 100% Automated Diagnostic System Defining the Future Gold Standard, Debuts inChicago, July 28–31 * Unifying global diagnostic data - STAgora™, the big data platform set to transform the future of diagnostics * Offering early access to the new diagnostic parad...
2025-07-24 17:36
3107
Akeso Announces First Patient Enrollment in Phase III Trial of Ivonescimab for Pancreatic Cancer
HONG KONG, July 23, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce that the first patient has been enrolled in the pivotal/registration Phase III clinical trial (AK112-310/HARMONi-GI2) of ivonescimab, a first-in-class PD-1/VEGF bispecific antibody dev...
2025-07-24 09:14
1587
Scaling Self-Care Can Be a Game-Changer in Global Fight Against Non-Communicable Diseases
* Ahead of the upcoming UN General Assembly to set a new vision for non-communicable diseases, the Global Self-Care Federation is calling for self-care strategies to be integrated into health plans * Non-communicable diseases account for 76% of global deaths, and their impact continues to ris...
2025-07-24 07:01
1251
HBM9378/WIN378, a Long-Acting, Fully Human Anti-TSLP Antibody, Enters Global Phase 2 POLARIS Trial for Asthma
* Phase 2 POLARIS trial will evaluate the dosing, safety, and efficacy of HBM9378/WIN378 in patients with asthma, with an initial data readout expected in mid-2026 * HBM9378/WIN378 has the potential to be the first-to-market long-acting anti-TSLP antibody with twice-yearly dosing for asthma ...
2025-07-23 20:36
2301
Elevating Care: GuidelineX Showcases AI-Powered Clinical Decision Support System at HIMSS APAC 2025
KUALA LUMPUR, Malaysia, July 23, 2025 /PRNewswire/ -- At the HIMSS APAC 2025 conference, GuidelineX made a powerful impact with its next-generation, AI-native Clinical Decision Support System (AI-CDSS). In her keynote, "Empowering Clinicians and Elevating Care: AI-Based Clinical Decision Support ...
2025-07-23 18:00
2353
Singapore-Based Innovative Biomedical Start-Up Achieves 'Strategic Triumph' to Conquer Chinese Med-Tech Market
* NMPA grants Syntellix product approval for the world's most important future market with more than 1.4 billion people * Syntellix' product approval for China is the largest and most important success in the company's history; product approval inChina was the company's most important strat...
2025-07-23 15:35
3068
Landmark Trial Demonstrates Efficacy of Microcurrent Therapy in Heart Failure: C-MIC II Results Published in the European Journal of Heart Failure
ZUG, Switzerland, July 23, 2025 /PRNewswire/ -- Berlin Heals and the C-MIC II Investigators today announced the publication of the C-MIC II trial results in the European Journal of Heart Failure. The study, titled "Cardio-microcurrent Device Treatment for Heart Failure with Reduced Ejection Fract...
2025-07-23 15:00
1566
Week's Top Stories
Most Reposted
Never Miss a Message: Agoda's Customer Support Now Travels With You
[Picked up by 328 media titles]
2026-02-24 12:00
HBX Group and Traveloka expand strategic partnership to deepen APAC supply and accelerate global distribution
[Picked up by 310 media titles]
2026-02-26 09:30
Amadeus acquires SkyLink to accelerate the deployment of AI in travel
[Picked up by 308 media titles]
2026-02-26 19:57
Klook and Osaka Convention & Tourism Bureau sign MoU to advance inbound tourism and foster socio-economic development throughout Osaka Prefecture
[Picked up by 302 media titles]
2026-02-24 16:13
SMU and Fudan Launch Region's First Tech-Focused DBA
[Picked up by 300 media titles]
2026-03-02 09:15Most Read
COLUMBIA ASIA HOSPITAL BUKIT JALIL LAUNCHES NEW CATH LAB TO STRENGTHEN HEART CARE SERVICES
2026-03-02 14:24
7738
NYSE Content Update: AI Data Platform DDN Appoints Guido Torrini as Finance Chief
2026-02-24 22:08
7169
